Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal - Roche Holding (OTC:RHHBY)
Roche Holding AG (OTC: RHHBY) inked a deal to acquire
Source: benzinga.com
Page 41 - Roivant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Roivant Sciences Today - Breaking & Trending Today
European Midday Briefing : Stocks Weighed by Earnings Disappointment - Today
MARKET WRAPS Stocks: European stocks were weaker again on Monday following some disappointing corporate news and as Israel ramped up its bombing of targets in Gaza. Philips said it... -October 23, 2023 at 06:00 am EDT - MarketScreener
Source: marketscreener.com
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Bln -- Update
By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion as the Swiss...
Source: marketwatch.com
Roche pays $7.1B up front for Telavant and its IBD drug
For a whopping $7.1 billion up front, Roche AG is buying Telavant Holdings Inc., a firm that is owned by Roivant Sciences Ltd. and Pfizer Inc. The deal also includes $150 million on the back end, and Roche gains rights to develop, manufacture and commercialize a fully human monoclonal antibody targeting tumor necrosis factor-like ligand 1A, RVT-3101, for treating inflammatory bowel disease (IBD) and possibly other diseases in the U.S. and Japan. Pfizer retains the rights for the rest of the world.
Source: bioworld.com
Roivant surges as Vivek Ramaswamy-found firm sells bowel disease drug for $7.1 billion
Roivant, the drug developer founded by Republican Presidential candidate Vivek Ramaswamy, has sold the rights to its bowel disease treatment for $7.1 billion.
Source: kilgorenewsherald.com